KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) Invested Capital (2020 - 2025)

Recursion Pharmaceuticals' Invested Capital history spans 6 years, with the latest figure at $1.1 billion for Q4 2025.

  • For Q4 2025, Invested Capital rose 9.27% year-over-year to $1.1 billion; the TTM value through Dec 2025 reached $1.1 billion, up 9.27%, while the annual FY2025 figure was $1.1 billion, 9.27% up from the prior year.
  • Invested Capital reached $1.1 billion in Q4 2025 per RXRX's latest filing, up from $1.1 billion in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $1.1 billion in Q4 2025 to a low of -$233.0 million in Q1 2021.
  • Average Invested Capital over 5 years is $589.7 million, with a median of $513.2 million recorded in 2022.
  • The largest YoY upside for Invested Capital was 503.11% in 2021 against a maximum downside of 64.82% in 2021.
  • A 5-year view of Invested Capital shows it stood at $542.9 million in 2021, then decreased by 10.52% to $485.8 million in 2022, then dropped by 4.6% to $463.5 million in 2023, then surged by 125.08% to $1.0 billion in 2024, then grew by 9.27% to $1.1 billion in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Invested Capital are $1.1 billion (Q4 2025), $1.1 billion (Q3 2025), and $927.9 million (Q2 2025).